D-Lin-MC3-DMA (GMP Like) 

D-Lin-MC3-DMA (GMP Like) is the GMP Like class D-Lin-MC3-DMA (HY-112251). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.

Preparation of MC3 Lipid Nanoparticles

Here we provide lipid molar ratios for LNPs in FDA-approved Patisiran (a siRNA targets the transthyretin (TTR) mRNA). The molar ratio of lipids in this formulation is D-Lin-MC3-DMA : DSPC : Cholesterol : PEG2000-C-DMG = 50 : 10 : 38.5 : 1.5^[1], and RNA to lipid weight ratio is 0.05 (wt/wt).

A. Lipid Mixture Preparation

1. Dissolve lipids in ethanol and prepare 10 mg/m stock solutions. The lipid stock solutions can be stored at 20°C for later use.

Note 1: The ionizable lipid is usually a liquid. Due to the viscosity, it should always be weighed rather than relying on the autopipette volume.

Note 2: Cholesterol in solution should be kept warm (>37°C) to maintain fluidity. Transfer the cholesterol solution promptly to avoid cooling.

2. Prepare the lipid mixture solution as described. For each mL of lipid mixture add the following: 548 μL of 10mg/mL D-Lin-MC3-DMA (HY-112251), 254 μL of 10mg/mL Cholesterol (HY-N0322), 134 μL of 10mg/mL DSPC (HY-W040193), and 64 μL of PEG2000-C-DMG (HY-145411) ^[2]. Mix the solutions thoroμghly to achieve a clear solution. This mixture contains 10 mg of total lipid.

Note 3: The choice of lipids and ratios may be changed as desired and this will affect the LNP properties (size, polydispersity, and efficacy) and the amount of mRNA required.

B. siRNA Preparation

1. Prepare a 166.7 μg/mL siRNA solution with 100 mM pH 5 sodium acetate buffer.

Note 4: The lipid:siRNA weight ratio influences the encapsulation efficiency. Other weight ratios may be prepared as alternative formulations and should be adjusted accordingly by user.

C. Mixing

There are three commonly used methods to achieve rapid mixing of the solutions: the pipette mixing method, the vortex mixing method, and the microfluidic mixing method. All these mixing methods can be used for various applications.

It is important to note that pipette mixing method and vortex mixing method may yield more heterogeneous LNPs with lower encapsulation efficiencies and is prone to variability. Microfluidic devices enable rapid mixing in a highly controllable, reproducible manner that achieves homogeneous LNPs and high encapsulation efficiency. Within these devices, the ethanolic lipid mixture and aqueous solution are rapidly combined in individual streams. LNPs are formed as the two streams mix and are then collected into a single collection tube.

1. Pipette Mixing Method:

1.1. Pipette 3 mL of the siRNA solution and quickly add it into 1 mL of the lipid mixture solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) Pipette up and down rapidly for 20-30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

2. Vortex Mixing Method:

1.1. Vortex 3 mL of siRNA solution at a moderate speed on the vortex mixer. Then, Quickly add 1 mL of the lipid mixture solution into the vortexing solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.). Continue vortexing the resulting dispersion for another 20-30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

3. Microfluidic Mixing Method:

1.1 The 3 mL of siRNA buffer solution and 1 mL of the lipid mixture solution were mixed at a total flow rate of 12 mL/min (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) in a microfluidic device.

Note 5: Parameters such as the flow rate ratio and total flow rate can be altered to fine-tune LNPs.

1.2. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

Reference

1. Curr Issues Mol Biol. 2022 Oct 19;44(10):5013-5027.

2. Curr Protoc. 2023;3(9):e898.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lipid nanoparticles (LNPs) containing distearoylphosphatidlycholine (DSPC), and ionizableamino-lipids such as dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA) are potent siRNA delivery vehicles in vivo. LNP-siRNA systems optimize to achieve maximum gene silencing potency in hepatocytesfollowing IV administration in mice contain DLin-MC3-DMA (MC3), DSPC, cholesterol and a polyethyleneglycol (PEG)-lipid at mole ratios of 50/10/38.5/1.5. DLin-MC3-DMA exhibits an optimized pK_a value that leads to dramatically enhanced potency^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

642.09

C₄₃H₇₉NO₂

1224606-06-7

O=C(OC(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC)CCCN(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kulkarni JA, et al. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017 May;13(4):1377-1387.  [Content Brief]

  [2]. Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells. Mol Pharm. 2022;19(7):2175-2182.  [Content Brief]